Moleculin Biotech, Inc. — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. The filing was signed March 24, 2021. Moleculin is a clinical-stage pharmaceutical company developing treatments for resistant cancers and viruses; it had no approved products or product sales.
Financial performance and position
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $12.8 million | $11.0 million |
| General and administrative expense | $6.8 million | $6.3 million |
| Total operating expenses | $19.7 million | $17.5 million |
| Net loss | $17.4 million | $13.2 million |
| Net loss per share, basic and diluted | $1.76 | $1.95 |
| Cash used in operating activities | $17.8 million | $17.2 million |
| Cash and cash equivalents at year-end | $15.2 million | $10.7 million |
There were no product revenues, so sales margins are not meaningful. The loss widened as operating costs rose; the lower per-share loss reflects a larger weighted-average share count. The 2020 net loss included a $2.3 million noncash gain from revaluing warrant liabilities, versus a $4.1 million gain in 2019.
At December 31, 2020, current assets were $17.2 million and current liabilities were $2.9 million. Total liabilities were $11.3 million, including an $8.2 million long-term warrant liability and $0.3 million in operating lease liabilities; the filing reports no conventional borrowings. Stockholders’ equity was $17.8 million, with an accumulated deficit of $56.9 million.
Financing activities provided $22.5 million in 2020, primarily from stock sales. Subsequent to year-end, the company reported $80.9 million of gross equity proceeds, including a February 2021 public offering and full exercise of the underwriters’ option. Management said year-end cash plus subsequent funding was expected to support projected operating needs through at least 2023, subject to spending and development assumptions.
Material changes and business developments
- R&D expense increased by $1.8 million, primarily due to more clinical-trial activity, sponsored research, drug manufacturing and two additional R&D employees. G&A expense increased by $0.5 million, partly offset by lower pandemic-related travel costs.
- Operating cash use rose by $0.6 million. Cash increased by $4.4 million during 2020, supported by equity financing.
- A one-for-six reverse stock split took effect January 29, 2021. The filing presents share data retrospectively for the split. Shares outstanding were 28,444,425 on March 11, 2021.
- At year-end, the company had five clinical trials underway or concluded during 2020. Its 2021 plan anticipated up to eight trials underway or approved, including physician-sponsored studies.
Outlook, clinical programs and key risks
- Annamycin: The U.S. Phase 1 AML study met its safety objective and was concluded, while the European Phase 1/2 study continued dose escalation. The company reported no observed cardiotoxicity among the first 19 assessed patients, including patients treated above the FDA’s lifetime anthracycline dose limit. However, two patients in the 240 mg/m² Polish cohort experienced liver-related dose-limiting toxicities; no additional patients were to be enrolled at that dose, and the company planned to test an intermediate dose. Preliminary AML results included 38% of 13 relapsed patients achieving a CRi, partial response or bridge to transplant; these results are early and subject to review.
- The FDA allowed a U.S. Phase 1b/2 Annamycin trial for soft-tissue sarcoma lung metastases to proceed. The company anticipated starting it in the first half of 2021 and planned a European investigator-funded study. It also planned an Annamycin-plus-Ara-C AML study in Europe. Promising animal results, including in metastatic osteosarcoma, are preclinical and do not establish human efficacy.
- WP1066: Two physician-sponsored Phase 1 brain-tumor trials were underway. The adult GBM study could be delayed after its sponsoring physician left MD Anderson; continuation and transfer of the IND were uncertain. One pediatric DIPG patient showed an apparent response, which the company cautioned was a single preliminary observation.
- WP1220: In a five-subject CTCL proof-of-concept study, the company reported a 45% objective response rate and 100% clinical benefit rate. It was seeking a partner for further study and could fund additional work itself if unsuccessful.
- WP1122: The company was pursuing cancer and potential antiviral development. FDA feedback indicated that a validated COVID-19 animal-model efficacy result may be needed before a U.S. IND; limited access to testing could delay trials. The company was also considering development outside the U.S. and expected to pursue an IND or foreign equivalent during 2021, subject to regulatory and preclinical work.
- Funding and dilution: The company expects continuing losses and negative operating cash flows and will require substantial capital to advance its pipeline. Financing may be unavailable or dilutive. The 2021 equity proceeds materially increased funding but also increased the share count.
- Other risks: Development and approval remain uncertain; trials face patient-recruitment and COVID-19 disruption risks; manufacturing depends on third parties; key intellectual property is licensed, and Annamycin’s composition-of-matter patent has expired. The company also disclosed related-party licensing relationships, including WPD and Animal Life Sciences, affiliates of a founder.
Management reported effective disclosure controls and internal control over financial reporting at December 31, 2020, and said a previously reported segregation-of-duties material weakness had been remediated. The independent auditor issued an unqualified opinion on the financial statements; it did not audit internal-control effectiveness.
Investor verification checklist
- Review the complete audited statements and subsequent-event disclosures to reconcile the $80.9 million gross post-year-end equity proceeds with net cash available, offering costs and dilution.
- Track cash burn against management’s stated funding horizon through at least 2023 and reassess it as trial plans and spending change.
- Verify final, quality-reviewed Annamycin safety and efficacy data, including the 240 mg/m² liver toxicities, dose selection and regulatory path.
- Confirm whether planned trials began, particularly the sarcoma, AnnAraC and WP1122 studies, and whether the adult WP1066 GBM program continued after the sponsor’s departure.
- Distinguish small-sample or preclinical findings from validated clinical outcomes; confirm the WP1220 study’s follow-on plans and any partnership.
- Assess outstanding warrants, options, related-party arrangements, license obligations and the company’s dependence on MD Anderson and contract manufacturers.